Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer
BACKGROUND: Previous studies have shown that branched-chain amino acid transferase 1 (BCAT1) is associated with tumour progression in triple-negative breast cancer (TNBC). Furthermore, CD133 has emerged as a novel cancer stem cell marker for indicating tumour progression. However, the prognostic significance of these two markers remains to be verified. This study was conducted to investigate the correlation between BCAT1 and CD133 expression and clinicopathological features, as well as the prognosis of patients with TNBC.
METHODS: The study cohort included 291 patients with TNBC. Tissue microarrays were constructed for both cancer and normal tissues. The expression of BCAT1 and CD133 was detected by immunohistochemical staining, and the levels were evaluated using an H-scoring system. Cut-off points for BCAT1 and CD133 expression were determined using receiver operating characteristic curves.
RESULTS: The median follow-up time for the study participants was 68.73 months (range: 1.37-103.6 months). The 5-year disease-free survival (DFS) and overall survival (OS) rates of the 291 patients with TNBC were 72.51 and 82.47%, respectively. Higher levels of BCAT1 and CD133 expression independently indicated shorter DFS and OS. High levels of both BCAT1 and CD133 expression were detected in 36 (12.37%) patients, who had significantly shorter DFS and OS (both P < 0.001) compared to other patients.
CONCLUSION: BCAT1 and CD133 can be considered as biomarkers with prognostic significance for TNBC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
BMC cancer - 20(2020), 1 vom: 22. Juni, Seite 584 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Song, Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AC133 Antigen |
|---|
| Anmerkungen: |
Date Completed 23.02.2021 Date Revised 29.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-020-07070-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311498221 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311498221 | ||
| 003 | DE-627 | ||
| 005 | 20240329233005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-020-07070-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM311498221 | ||
| 035 | |a (NLM)32571264 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Song, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2021 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Previous studies have shown that branched-chain amino acid transferase 1 (BCAT1) is associated with tumour progression in triple-negative breast cancer (TNBC). Furthermore, CD133 has emerged as a novel cancer stem cell marker for indicating tumour progression. However, the prognostic significance of these two markers remains to be verified. This study was conducted to investigate the correlation between BCAT1 and CD133 expression and clinicopathological features, as well as the prognosis of patients with TNBC | ||
| 520 | |a METHODS: The study cohort included 291 patients with TNBC. Tissue microarrays were constructed for both cancer and normal tissues. The expression of BCAT1 and CD133 was detected by immunohistochemical staining, and the levels were evaluated using an H-scoring system. Cut-off points for BCAT1 and CD133 expression were determined using receiver operating characteristic curves | ||
| 520 | |a RESULTS: The median follow-up time for the study participants was 68.73 months (range: 1.37-103.6 months). The 5-year disease-free survival (DFS) and overall survival (OS) rates of the 291 patients with TNBC were 72.51 and 82.47%, respectively. Higher levels of BCAT1 and CD133 expression independently indicated shorter DFS and OS. High levels of both BCAT1 and CD133 expression were detected in 36 (12.37%) patients, who had significantly shorter DFS and OS (both P < 0.001) compared to other patients | ||
| 520 | |a CONCLUSION: BCAT1 and CD133 can be considered as biomarkers with prognostic significance for TNBC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BCAT1 | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a CD133 | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Triple-negative breast cancer | |
| 650 | 7 | |a AC133 Antigen |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a PROM1 protein, human |2 NLM | |
| 650 | 7 | |a BCAT1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.6.1. |2 NLM | |
| 650 | 7 | |a Transaminases |2 NLM | |
| 650 | 7 | |a EC 2.6.1.- |2 NLM | |
| 700 | 1 | |a Zhao, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yali |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Liangrui |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Qiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 20(2020), 1 vom: 22. Juni, Seite 584 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:1 |g day:22 |g month:06 |g pages:584 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-020-07070-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 1 |b 22 |c 06 |h 584 | ||